3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
175
HER2-positive Breast Cancer
16
Neoplasms
11
Neoplasm Metastasis
10
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
decitabine and cedazuridine drug combination
1
apalutamide
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Risk Assessment
1
Radiotherapy
1
Preoperative Exercise
1
Opdualag
1
Nutritional Support
1
Nivolumab
1
Injections, Subcutaneous
1
Exercise
1
Ethanol
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Patient Preference
×
pertuzumab
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts